tradingkey.logo
搜索

Nexalin Technology Inc

NXL
添加自选
0.340USD
-0.002-0.58%
收盘 07-31 16:00美东报价延迟15分钟
7.00M总市值
亏损市盈率 TTM

关于 Nexalin Technology Inc 公司

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc简介

公司代码NXL
公司名称Nexalin Technology Inc
上市日期Sep 16, 2022
CEOWhite (Mark)
员工数量6
证券类型Ordinary Share
年结日Sep 16
公司地址1776 Yorktown
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77056
电话18322600222
网址https://nexalin.com
公司代码NXL
上市日期Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

常见问题

Nexalin Technology Inc的前五大股东是谁?

Nexalin Technology Inc 的前五大股东如下:Ms. Marilyn Elson

有多少机构持有Nexalin Technology Inc(NXL)的股份?

截至2026Q1,共有43家机构持有Nexalin Technology Inc的股份,合计持有的股份价值约为1.43M,占公司总股份的6.94%。与2025Q4相比,机构持股有所增加,增幅为524945.00。

哪个业务部门对Nexalin Technology Inc的收入贡献最大?

在2026Q1,Device Sales业务部门对Nexalin Technology Inc的收入贡献最大,创收136.00K,占总收入的45.09%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有